Johns Hopkins researchers found that a drug first developed to treat Alzheimer's disease, schizophrenia and sickle cell anemia reduced obesity and fatty liver in mice and improved their heart function -- without changes in food intake or daily activities.
These findings, published in the Journal of Clinical Investigation, reveal that a chemical inhibitor of the PDE9 enzyme encourages cells to burn more fat. This happened in male mice and in female mice whose sex hormones were reduced by removing the ovaries, thus mimicking menopause. It is known that postmenopausal women are exposed to an increased risk of obesity around the waist, as well as the risk of cardiovascular and metabolic diseases. PDE9 inhibition did not cause these changes in ovariectomized female mice, so female sex hormone status was important in the study.
"Currently, there is no pill that has been proven to be successful in treating severe obesity. It is a global health problem that increases the risk of many other diseases," says senior researcher David Kass, M.D., the Abraham and Virginia Weiss Professor of Cardiology at Johns Hopkins University School of Medicine. (thebrighterside.news)... the text is followed by an appropriate picture or clip